Sarah Gilbert
Payments from drug & device makers
Across 397 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$839
- Teva Pharmaceuticals USA, Inc.$731
- Lundbeck LLC$570
- Impel Pharmaceuticals LLC$480
- Lilly USA, LLC$331
- plus $677 from 8 others
What the payments were for
- Food & beverage$6,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 158 | $2,827 |
| Pfizer | 52 | $839 |
| Teva Pharmaceuticals USA, Inc. | 85 | $731 |
| Lundbeck LLC | 29 | $570 |
| Impel Pharmaceuticals LLC | 28 | $480 |
| Lilly USA, LLC | 15 | $331 |
| Axsome Therapeutics, Inc. | 11 | $308 |
| Scilex Pharmaceuticals Inc. | 9 | $200 |
| Currax Pharmaceuticals LLC | 4 | $63 |
| Impel Pharmaceuticals Inc. | 2 | $34 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,455 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 108 | $77,437 |
| UbrelvyUbrogepant | 44 | $62,769 |
| Aimovig AutoinjectorErenumab-Aooe | 47 | $45,037 |
| QuliptaAtogepant | 38 | $42,231 |
| Nurtec OdtRimegepant Sulfate | 37 | $40,656 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 39 | $34,341 |
| BotoxOnabotulinumtoxina | 13 | $17,234 |
| ZavzpretZavegepant Hcl | 12 | $13,673 |
| Eletriptan HbrEletriptan Hydrobromide | 11 | $1,846 |
| Candesartan Cilexetil | 33 | $1,733 |
| Naratriptan Hcl | 44 | $1,678 |
| RizatriptanRizatriptan Benzoate | 48 | $1,572 |
| Zolmitriptan | 19 | $1,160 |
| Gabapentin | 71 | $995 |
| Acetazolamide | 14 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $2,827 | $122,23595 claims |
| PfizerNurtec Odt, Zavzpret | $839 | $54,32949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Jillian OakleafTulsa$15K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Jaclyn DrassTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.